Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNE1 | P15382 | 1/20 | 0.44 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.44 |
| ▸ | WDR5 | P61964 | 10/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6018062 | 0.94 | WDR5 (0.46) | KCNE1CCR1KCNQ1WDR5CNR1 | |
| SCHEMBL6017825 | 0.92 | KCNE1 (0.46) | KCNE1CCR1KCNQ1WDR5KCNH2 | |
| SCHEMBL6017883 | 0.90 | KCNE1 (0.52) | KCNE1CCR1KCNQ1KCNH2MEN1 | |
| SCHEMBL6017757 | 0.82 | KMT2A (0.39) | KCNE1CCR1KCNQ1WDR5KCNH2 | |
| SCHEMBL6017779 | 0.80 | KCNE1 (0.42) | KCNE1CCR1KCNQ1WDR5CNR1 | |
| SCHEMBL6017619 | 0.80 | CNR1 (0.43) | KCNE1CCR1KCNQ1WDR5CNR1 | |
| SCHEMBL6018089 | 0.79 | TSHR (0.45) | KCNE1CCR1KCNQ1WDR5CNR1 | |
| SCHEMBL6017692 | 0.79 | MMP1 (0.47) | WDR5CNR1CNR2MEN1KMT2A | |
| SCHEMBL6017958 | 0.79 | WDR5 (0.45) | KCNE1CCR1KCNQ1WDR5KCNH2 | |
| SCHEMBL6017747 | 0.78 | CNR1 (0.40) | KCNE1CCR1KCNQ1WDR5CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7037908-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| US-20040229892-A1 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229892-A1 | Pyrimidine carboxamides; 5-hydroxy-2-(2-(1,1-Dioxo-6-[1,2]thiazinan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamides; AIDS; AIDS related complex | DUT, CDK6, TYMS | KCNE1 3647/4885CCR1 1187/4885KCNQ1 2858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.